TL;DR: Aetna, a CVS Health company, modified CPB 0711 governing mecasermin (Increlex) coverage, with an effective date of September 26, 2025. Here's what billing teams need to know.
Aetna updated its mecasermin (Increlex) coverage policy under CPB 0711 on September 26, 2025. Mecasermin is recombinant human insulin-like growth factor-1 (rhIGF-1), used to treat severe primary IGF-1 deficiency and growth failure in children. Unfortunately, the source document returned a 404 error during retrieval, which means the specific line-by-line changes, updated medical necessity criteria, and any revised prior authorization requirements are not available from the public-facing policy page at this time.
This post covers what we know about the policy structure, what billing teams should do right now, and how to get the full updated criteria directly from Aetna before September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Mecasermin (Increlex) — CPB 0711 |
| Policy Code | CPB 0711 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium — specialty pharmacy and pediatric endocrinology billing teams should verify criteria before the effective date |
| Specialties Affected | Pediatric endocrinology, specialty pharmacy, rare disease billing |
| Key Action | Pull the current CPB 0711 policy directly from Aetna's provider portal and confirm your prior authorization workflows reflect any updated criteria before September 26, 2025 |
Aetna Mecasermin Coverage Criteria and Medical Necessity Requirements 2025
The Aetna mecasermin (Increlex) coverage policy under CPB 0711 governs one of the most tightly managed specialty drugs in pediatric endocrinology billing. Mecasermin reimbursement has historically required strict medical necessity documentation, and Aetna is not alone in that approach — most major payers treat rhIGF-1 therapy as a high-cost specialty drug with narrow covered indications.
Because the policy document was inaccessible at time of publication, we cannot confirm the exact updated medical necessity criteria from the September 26, 2025 revision. What we can tell you is that CPB 0711 Aetna has historically required documented severe primary IGF-1 deficiency, confirmed through IGF-1 serum levels and stimulation testing, along with growth failure meeting defined height-for-age thresholds. Prior authorization has been standard for mecasermin under virtually every Aetna plan that covers it at all.
If your team bills mecasermin for pediatric patients, do not assume the criteria you've been working with are still current after September 26, 2025. A policy modification — even a subtle one — can shift a claim from covered to denied if your documentation doesn't match the updated language.
Prior authorization requirements for mecasermin are not optional. Aetna requires prior auth before initiating therapy, and any change to the coverage policy criteria can affect whether existing authorizations remain valid for new treatment courses. Confirm with your Aetna provider relations contact whether current authorizations are grandfathered or need resubmission under the revised criteria.
Aetna Mecasermin (Increlex) Exclusions and Non-Covered Indications
CPB 0711 has historically excluded mecasermin for secondary IGF-1 deficiency — cases where low IGF-1 is caused by growth hormone deficiency rather than primary IGF-1 deficiency. That distinction matters in documentation. If a patient's workup shows growth hormone deficiency as the underlying cause, mecasermin is not covered under this policy. Growth hormone therapy is the appropriate covered treatment in that scenario.
Use of mecasermin for growth failure not meeting the primary IGF-1 deficiency threshold, or for off-label indications such as type 1 or type 2 diabetes management, has been considered experimental or investigational under prior versions of CPB 0711. Whether the September 26, 2025 revision changes any of these exclusions is unknown until the policy document is accessible.
This is exactly the kind of ambiguity that creates claim denial risk. If you're billing mecasermin for any indication other than severe primary IGF-1 deficiency, talk to your compliance officer before the effective date.
Coverage Indications at a Glance
The table below reflects the historical coverage structure of CPB 0711. Because the September 26, 2025 document was unavailable, these rows are based on the known policy framework — not the updated text. Treat this as a baseline only. Verify each row against the live policy before billing after September 26, 2025.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Severe primary IGF-1 deficiency with growth failure in children | Covered (when criteria met) | Not available from current data | Prior authorization required; documentation of IGF-1 levels and growth failure required |
| Secondary IGF-1 deficiency (GH deficiency as cause) | Not Covered | Not available from current data | GH therapy is the covered alternative |
| Off-label use (e.g., diabetes management) | Experimental / Not Covered | Not available from current data | Historical exclusion; verify against updated policy |
| Mecasermin analog (mecasermin rinfabate — iPlex) | Not Covered | Not available from current data | Has been excluded under prior CPB 0711 versions |
Note: This table reflects the historical policy structure. The specific updated criteria from the September 26, 2025 revision were not available at time of publication. Verify all indications against the current CPB 0711 document before submitting claims.
Aetna Mecasermin Billing Guidelines and Action Items 2025
The policy document being unavailable is not a reason to wait. Here's what your billing team should do right now.
| # | Action Item |
|---|---|
| 1 | Pull CPB 0711 directly from Aetna's provider portal before September 26, 2025. Log in to Aetna's provider site and search for CPB 0711. The public-facing URL returned a 404, but the authenticated provider portal typically has current policy documents. If you can't access it there, call your Aetna provider relations representative and request the updated policy in writing. |
| 2 | Audit your active mecasermin prior authorizations before the effective date. If you have patients currently authorized for mecasermin therapy, confirm whether those authorizations carry forward under the revised criteria or require resubmission. Don't assume they're valid until you've checked. |
| 3 | Update your medical necessity documentation templates to match the new criteria. Once you have the updated CPB 0711 language, compare it to your current intake forms and clinical documentation requirements. If Aetna has tightened IGF-1 threshold criteria or added new testing requirements, your templates need to reflect that before the first claim goes out under the new policy. |
| 4 | Flag HCPCS J2170 in your charge capture system for review. Mecasermin (Increlex) is billed under HCPCS J2170. This code is not listed in the current policy data due to the document error, but J2170 is the standard billing code for this drug. Confirm this code and any applicable dosing units against the updated policy once you retrieve it. Mecasermin billing under J2170 will be subject to the updated criteria as of September 26, 2025. |
| 5 | Check your specialty pharmacy coordination workflows. Mecasermin is typically dispensed through specialty pharmacy channels. If your practice coordinates with a specialty pharmacy for this drug, they also need to know about the policy update. A denial at the pharmacy level creates downstream problems for your clinical team and the patient. |
| 6 | If you can't retrieve the updated policy before the effective date, hold mecasermin claims for new starts until you can. A clean hold beats a preventable claim denial every time. The reimbursement on mecasermin is significant — this is not a low-dollar code where you absorb a denial and move on. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Mecasermin (Increlex) Under CPB 0711
The policy data provided for CPB 0711 returned a 404 error and includes no codes. The code tables below are therefore incomplete. Do NOT submit claims based on this section alone.
Covered HCPCS Codes (Based on Standard Mecasermin Billing — Verify Against Updated Policy)
The policy does not list specific codes in the available data. Based on standard industry billing practices for mecasermin, the following code is typically used — but you must confirm this against the current CPB 0711 document before billing:
| Code | Type | Description |
|---|---|---|
| J2170 | HCPCS | Injection, mecasermin, 1 mg (standard industry code — not confirmed in current CPB 0711 data) |
This code is listed for reference only. It was not extracted from the CPB 0711 policy document. Verify with Aetna before use.
Key ICD-10-CM Diagnosis Codes
No ICD-10 codes were available from the policy data. Historically, the relevant diagnosis codes for mecasermin coverage have included E34.3 (Short stature due to endocrine disorder) and related IGF-1 deficiency codes — but these must be confirmed against the updated policy. Do not code from this table without verifying against the live CPB 0711 document.
A Note on the Policy Data Gap
The source document for CPB 0711 returned a 404 error. That's not a minor inconvenience — it means this post cannot give you the full updated criteria, and you need to go get them directly from Aetna before September 26, 2025.
The real issue here is timing. A policy modification with a September 26 effective date means claims submitted on or after that date will be adjudicated under the new rules. If you don't know what changed, you're billing blind. Given that mecasermin is a high-cost specialty drug with narrow covered indications, the financial exposure from a denied claim or an authorization that doesn't align with updated criteria is real.
Don't let a 404 error be the reason your billing team misses this change. Get the document, read it, and update your workflows before the effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.